Diagnostic anoctamin-5 protein defect in patients with ANO5-mutated muscular dystrophy

A. Vihola, H. Luque, M. Savarese, S. Penttilä, M. Lindfors, F. Leturcq, B. Eymard, G. Tasca, B. Brais, T. Conte, K. Charton, I. Richard, B. Udd

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aims: Previously, detection of ANO5 protein has been complicated by unspecific antibodies, most of which have not identified the correct protein. The aims of the study were to specify ANO5 protein expression in human skeletal muscle, and to investigate if the ANO5 protein levels are affected by different ANO5 mutations in anoctaminopathy patients. Methods: Four different antibodies were tested for ANO5 specificity. A sample preparation method compatible with membrane proteins, combined with tissue fractionation was used to determine ANO5 expression in cell cultures expressing ANO5, in normal muscles and eight patient biopsies with six different ANO5 mutations in homozygous or compound heterozygous states, and in other dystrophies. Results: Only one specific monoclonal N-terminal ANO5 antibody was efficient in detecting the protein, showing that ANO5 is expressed as a single 107 kD polypeptide in human skeletal muscle. The truncating mutations c.191dupA and c.1261C>T were found to abolish ANO5 expression, whereas the studied point mutations had variable effects; however, all the ANO5 mutations resulted in clearly reduced ANO5 expression in the patient muscle membrane fraction. Attempts to detect ANO5 using immunohistochemistry were not yet successful. Conclusions: The data presented here indicate that the ANO5 protein expression is decreased in ANO5-mutated muscular dystrophy and that most of the non-truncating pathogenic ANO5 mutations likely destabilize the protein and cause its degradation. The method described here allows direct analysis of human ANO5 protein, which can be used in diagnostics, for evaluating the pathogenicity of the potentially harmful ANO5 variants of uncertain significance.

Original languageEnglish
Pages (from-to)441-448
Number of pages8
JournalNeuropathology and Applied Neurobiology
Volume44
Issue number5
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Muscular Dystrophies
Mutation
Proteins
Antibodies
Skeletal Muscle
Muscles
Point Mutation
Virulence
Membrane Proteins
Cell Culture Techniques
Immunohistochemistry
Biopsy
Peptides
Membranes

Keywords

  • ANO5
  • DMM3
  • LGMD2L
  • limb-girdle muscular dystrophy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

Vihola, A., Luque, H., Savarese, M., Penttilä, S., Lindfors, M., Leturcq, F., ... Udd, B. (2018). Diagnostic anoctamin-5 protein defect in patients with ANO5-mutated muscular dystrophy. Neuropathology and Applied Neurobiology, 44(5), 441-448. https://doi.org/10.1111/nan.12410

Diagnostic anoctamin-5 protein defect in patients with ANO5-mutated muscular dystrophy. / Vihola, A.; Luque, H.; Savarese, M.; Penttilä, S.; Lindfors, M.; Leturcq, F.; Eymard, B.; Tasca, G.; Brais, B.; Conte, T.; Charton, K.; Richard, I.; Udd, B.

In: Neuropathology and Applied Neurobiology, Vol. 44, No. 5, 01.08.2018, p. 441-448.

Research output: Contribution to journalArticle

Vihola, A, Luque, H, Savarese, M, Penttilä, S, Lindfors, M, Leturcq, F, Eymard, B, Tasca, G, Brais, B, Conte, T, Charton, K, Richard, I & Udd, B 2018, 'Diagnostic anoctamin-5 protein defect in patients with ANO5-mutated muscular dystrophy', Neuropathology and Applied Neurobiology, vol. 44, no. 5, pp. 441-448. https://doi.org/10.1111/nan.12410
Vihola, A. ; Luque, H. ; Savarese, M. ; Penttilä, S. ; Lindfors, M. ; Leturcq, F. ; Eymard, B. ; Tasca, G. ; Brais, B. ; Conte, T. ; Charton, K. ; Richard, I. ; Udd, B. / Diagnostic anoctamin-5 protein defect in patients with ANO5-mutated muscular dystrophy. In: Neuropathology and Applied Neurobiology. 2018 ; Vol. 44, No. 5. pp. 441-448.
@article{393bf84ee8454159a6605909934d5a95,
title = "Diagnostic anoctamin-5 protein defect in patients with ANO5-mutated muscular dystrophy",
abstract = "Aims: Previously, detection of ANO5 protein has been complicated by unspecific antibodies, most of which have not identified the correct protein. The aims of the study were to specify ANO5 protein expression in human skeletal muscle, and to investigate if the ANO5 protein levels are affected by different ANO5 mutations in anoctaminopathy patients. Methods: Four different antibodies were tested for ANO5 specificity. A sample preparation method compatible with membrane proteins, combined with tissue fractionation was used to determine ANO5 expression in cell cultures expressing ANO5, in normal muscles and eight patient biopsies with six different ANO5 mutations in homozygous or compound heterozygous states, and in other dystrophies. Results: Only one specific monoclonal N-terminal ANO5 antibody was efficient in detecting the protein, showing that ANO5 is expressed as a single 107 kD polypeptide in human skeletal muscle. The truncating mutations c.191dupA and c.1261C>T were found to abolish ANO5 expression, whereas the studied point mutations had variable effects; however, all the ANO5 mutations resulted in clearly reduced ANO5 expression in the patient muscle membrane fraction. Attempts to detect ANO5 using immunohistochemistry were not yet successful. Conclusions: The data presented here indicate that the ANO5 protein expression is decreased in ANO5-mutated muscular dystrophy and that most of the non-truncating pathogenic ANO5 mutations likely destabilize the protein and cause its degradation. The method described here allows direct analysis of human ANO5 protein, which can be used in diagnostics, for evaluating the pathogenicity of the potentially harmful ANO5 variants of uncertain significance.",
keywords = "ANO5, DMM3, LGMD2L, limb-girdle muscular dystrophy",
author = "A. Vihola and H. Luque and M. Savarese and S. Penttil{\"a} and M. Lindfors and F. Leturcq and B. Eymard and G. Tasca and B. Brais and T. Conte and K. Charton and I. Richard and B. Udd",
year = "2018",
month = "8",
day = "1",
doi = "10.1111/nan.12410",
language = "English",
volume = "44",
pages = "441--448",
journal = "Neuropathology and Applied Neurobiology",
issn = "0305-1846",
publisher = "Wiley Blackwell",
number = "5",

}

TY - JOUR

T1 - Diagnostic anoctamin-5 protein defect in patients with ANO5-mutated muscular dystrophy

AU - Vihola, A.

AU - Luque, H.

AU - Savarese, M.

AU - Penttilä, S.

AU - Lindfors, M.

AU - Leturcq, F.

AU - Eymard, B.

AU - Tasca, G.

AU - Brais, B.

AU - Conte, T.

AU - Charton, K.

AU - Richard, I.

AU - Udd, B.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Aims: Previously, detection of ANO5 protein has been complicated by unspecific antibodies, most of which have not identified the correct protein. The aims of the study were to specify ANO5 protein expression in human skeletal muscle, and to investigate if the ANO5 protein levels are affected by different ANO5 mutations in anoctaminopathy patients. Methods: Four different antibodies were tested for ANO5 specificity. A sample preparation method compatible with membrane proteins, combined with tissue fractionation was used to determine ANO5 expression in cell cultures expressing ANO5, in normal muscles and eight patient biopsies with six different ANO5 mutations in homozygous or compound heterozygous states, and in other dystrophies. Results: Only one specific monoclonal N-terminal ANO5 antibody was efficient in detecting the protein, showing that ANO5 is expressed as a single 107 kD polypeptide in human skeletal muscle. The truncating mutations c.191dupA and c.1261C>T were found to abolish ANO5 expression, whereas the studied point mutations had variable effects; however, all the ANO5 mutations resulted in clearly reduced ANO5 expression in the patient muscle membrane fraction. Attempts to detect ANO5 using immunohistochemistry were not yet successful. Conclusions: The data presented here indicate that the ANO5 protein expression is decreased in ANO5-mutated muscular dystrophy and that most of the non-truncating pathogenic ANO5 mutations likely destabilize the protein and cause its degradation. The method described here allows direct analysis of human ANO5 protein, which can be used in diagnostics, for evaluating the pathogenicity of the potentially harmful ANO5 variants of uncertain significance.

AB - Aims: Previously, detection of ANO5 protein has been complicated by unspecific antibodies, most of which have not identified the correct protein. The aims of the study were to specify ANO5 protein expression in human skeletal muscle, and to investigate if the ANO5 protein levels are affected by different ANO5 mutations in anoctaminopathy patients. Methods: Four different antibodies were tested for ANO5 specificity. A sample preparation method compatible with membrane proteins, combined with tissue fractionation was used to determine ANO5 expression in cell cultures expressing ANO5, in normal muscles and eight patient biopsies with six different ANO5 mutations in homozygous or compound heterozygous states, and in other dystrophies. Results: Only one specific monoclonal N-terminal ANO5 antibody was efficient in detecting the protein, showing that ANO5 is expressed as a single 107 kD polypeptide in human skeletal muscle. The truncating mutations c.191dupA and c.1261C>T were found to abolish ANO5 expression, whereas the studied point mutations had variable effects; however, all the ANO5 mutations resulted in clearly reduced ANO5 expression in the patient muscle membrane fraction. Attempts to detect ANO5 using immunohistochemistry were not yet successful. Conclusions: The data presented here indicate that the ANO5 protein expression is decreased in ANO5-mutated muscular dystrophy and that most of the non-truncating pathogenic ANO5 mutations likely destabilize the protein and cause its degradation. The method described here allows direct analysis of human ANO5 protein, which can be used in diagnostics, for evaluating the pathogenicity of the potentially harmful ANO5 variants of uncertain significance.

KW - ANO5

KW - DMM3

KW - LGMD2L

KW - limb-girdle muscular dystrophy

UR - http://www.scopus.com/inward/record.url?scp=85020167001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020167001&partnerID=8YFLogxK

U2 - 10.1111/nan.12410

DO - 10.1111/nan.12410

M3 - Article

AN - SCOPUS:85020167001

VL - 44

SP - 441

EP - 448

JO - Neuropathology and Applied Neurobiology

JF - Neuropathology and Applied Neurobiology

SN - 0305-1846

IS - 5

ER -